May 15th 2024
The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.
FDA’s Approval of Breyanzi Gives Some Patients With Lymphoma a ‘Life-Saving Therapy', Says Expert
July 8th 2022The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.
Kymriah Shows ‘Huge Potential’ for Patients With Heavily Pretreated, Relapsed Follicular Lymphoma
January 24th 2022Kymriah may represent a more effective option than currently available treatments for patients with heavily pretreated follicular lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Trading Places: A Father and Daughter's Journey with Lymphoma
October 30th 2020Bob Meyers and his daughter Leslie Watson have always been close. In fact, they live right down the street from one another in their Georgia neighborhood. So, when Watson received the diagnosis of clear cell carcinoma in the summer of 1996, and then follicular lymphoma later that fall, Meyers was there by her side as her devoted caregiver.
Tazverik a Safe and Effective Option for Heavily Pretreated Patients with Follicular Lymphoma
October 27th 2020In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.
Aliqopa in Combination with Rituxan Meets Primary End Point for Indolent Non-Hodgkin’s Lymphoma
October 16th 2020A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.